Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 4;15:1501679. doi: 10.3389/fimmu.2024.1501679

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Cuiffo, Maxwell, Yan, Guemiri, Boone, Bellet, Rivest, Cardia, Robert and Fricker

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

IT mPH-762 treatment elicits tumor control in a dose-associated manner in multiple syngeneic tumor models. mPH-762 was administered IT q3d as indicated. Anti-PD-1 mAb control was administered IP q3d as indicated. Tumors were measured 3x/week by caliper, and volumes calculated by V = (LxW2)/2. (A, B) Hepa1-6 model. (C, D) B16-OVA model. (E, F) CT26 model. (G) BP model (A, C, E, G) Group mean tumor volume ± SEM (N = as indicated) over time. (B, D, F) Tumor volume area under the curve (AUC) calculated for each animal by trapezoidal transformation over the indicated time period. Violin plots with individual animals and medians are shown. Statistical significance of differences in mean AUC were assessed by one-way ANOVA and Tukey’s or Dunnett’s (F) multiple comparisons post-hoc tests. ****p <0.0001; ***p <0.001; **p <0.01.